Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions

References

• Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst. Monogr.42, 101–104 (1975).
   PubMedGoogle Scholar
• Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol. Oncol.78(3 Pt 1), 269–274 (2000).
   PubMedGoogle Scholar
• Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin. Surg. Oncol.19(1), 42–48 (2000).
   PubMedGoogle Scholar
• Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med.363(10), 943–953 (2010).
   PubMed Web of Science ®Google Scholar
• Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol.42(2), 146–150 (1991).
   PubMed Web of Science ®Google Scholar
• Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur. J. Gynaecol. Oncol.17(5), 393–396 (1996).
   PubMedGoogle Scholar
• Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol.72(1), 93–99 (1999).
   PubMed Web of Science ®Google Scholar
• Kayikçioğlu F, Köse MF, Boran N, Çalişkan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer11(6), 466–470 (2001).
   PubMed Web of Science ®Google Scholar
• Vrščaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case–control study. Eur. J. Gynaecol. Oncol.23(5), 405–410 (2002).
   PubMedGoogle Scholar
• Morice P, Brehier-Ollive D, Rey A et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann. Oncol.14(1), 74–77 (2003).
   PubMed Web of Science ®Google Scholar
• Loizzi V, Cormio G, Resta L et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case–control study. Int. J. Gynecol. Cancer15(2), 217–223 (2005).
   PubMedGoogle Scholar
• Everett EN, French AE, Stone RL et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am. J. Obstet. Gynecol.195(2), 568–574; discussion 574–576 (2006).
   PubMedGoogle Scholar
• Inciura A, Simavicius A, Juozaityte E et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer6, 153 (2006).
   PubMedGoogle Scholar
• Steed H, Oza AM, Murphy J et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer16(Suppl. 1), 47–53 (2006).
   PubMedGoogle Scholar
• Hou JY, Kelly MG, Yu H et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol. Oncol.105(1), 211–217 (2007).
   PubMed Web of Science ®Google Scholar
• Colombo PE, Mourregot A, Fabbro M et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur. J. Surg. Oncol.35(2), 135–143 (2009).
   PubMed Web of Science ®Google Scholar
• Morice P, Dubernard G, Rey A et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg.197(6), 955–963 (2003).
   PubMedGoogle Scholar
• Kuhn W, Rutke S, Späthe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer92(10), 2585–2591 (2001).
   PubMed Web of Science ®Google Scholar
• Hegazy MA, Hegazi RA, Elshafei MA et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J. Surg. Oncol.3, 57 (2005).
   PubMedGoogle Scholar
• Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J. Obstet. Gynaecol. Res.32(1), 99–106 (2006).
   PubMedGoogle Scholar
• Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur. J. Gynaecol. Oncol.27(1), 25–28 (2006).
   PubMedGoogle Scholar
• Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol.103(3), 1070–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann. Surg. Oncol.16(8), 2315–2320 (2009).
   PubMed Web of Science ®Google Scholar
• Kehoe S. Treatments for gynaecological cancers. Best Pract. Res. Clin. Obstet. Gynaecol.20(6), 985–1000 (2006).
   PubMedGoogle Scholar
• Onda T, Matsumoto K, Shibata T et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J. Clin. Oncol.38(1), 74–77 (2008).
   PubMed Web of Science ®Google Scholar
• Onda T, Kamura T, Ishizuka N, Katsumata N, Fukuda H, Yoshikawa H. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J. Clin. Oncol.34(1), 43–45 (2004).
   PubMedGoogle Scholar
• Onda T, Kobayashi H, Nakanishi T et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol. Oncol.113(1), 57–62 (2009).
   PubMedGoogle Scholar
• Kumar L, Hariprasad R, Kumar S et al. Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): a Phase III randomized study. J. Clin. Oncol.(Meeting Abstracts)24(18 Suppl.), 15000 (2006).
   Google Scholar
• Kumar L, Hariprasad R, Kumar S et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): a prospective randomized study – interim results. J. Clin. Oncol.(Meeting Abstracts)25(18 Suppl.), 5531 (2007).
   PubMedGoogle Scholar
• Schwartz PE, Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol. Oncol.90(3), 644–650 (2003).
   PubMedGoogle Scholar
• Freedman OC, Dodge J, Shaw P et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecol. Oncol.119(1), 22–25 (2010).
   PubMedGoogle Scholar
• Donadio M, Bonardi G, Iberti V et al. The role of induction chemotherapy in inoperable ovarian cancer. Tumori75(6), 609–614 (1989).
   PubMedGoogle Scholar
• Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol. Oncol.37(3), 327–331 (1990).
   PubMed Web of Science ®Google Scholar
• Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin. Oncol. (R. Coll. Radiol.)5(4), 198–202 (1993).
   PubMedGoogle Scholar
• Pölcher M, Mahner S, Ortmann O et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer – a prospective multicenter Phase II trial (PRIMOVAR). Oncol. Rep.22(3), 605–613 (2009).
   PubMedGoogle Scholar
• Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol.11(1), 166–172 (1993).
   PubMed Web of Science ®Google Scholar
• Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer101(2), 346–352 (2004).
   PubMedGoogle Scholar
• Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol.96(2), 301–306 (2005).
   PubMed Web of Science ®Google Scholar
• Vergote I, De Wever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol.71(3), 431–436 (1998).
   PubMed Web of Science ®Google Scholar
• Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int. J. Gynecol. Cancer16(Suppl. 1), 35–40 (2006).
   PubMedGoogle Scholar
• Fagotti A, Ferrandina G, Fanfani F et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol.13(8), 1156–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol. Oncol.100(1), 33–37 (2006).
   PubMedGoogle Scholar
• Aletti GD, Eisenhauer EL, Santillan A et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol.120(1), 23–28 (2011).
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Lang J et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol.103(2), 559–564 (2006).
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Spirtos NM, Lin WC. ‘Optimal’ cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol.103(1), 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer115(6), 1234–1244 (2009).
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Gostout BS et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol.107(1), 77–85 (2006).
   PubMed Web of Science ®Google Scholar
• Onda T, Yoshikawa H, Yasugi T, Matsumoto K, Taketani Y. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Jpn J. Clin. Oncol.40(1), 36–41 (2010).
   PubMedGoogle Scholar
• Mazzeo F, Berlierè M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol. Oncol.90(1), 163–169 (2003).
   PubMed Web of Science ®Google Scholar
• Le T, Faught W, Hopkins L, Fung Kee Fung M. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int. J. Gynecol. Cancer15(5), 770–775 (2005).
   PubMedGoogle Scholar
• Le T, Alshaikh G, Hopkins L, Faught W, Fung MF. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann. Surg. Oncol.13(12), 1711–1716 (2006).
   PubMedGoogle Scholar
• Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol. Oncol.88(1), 9–16 (2003).
   PubMed Web of Science ®Google Scholar
• Tiersten AD, Liu PY, Smith HO et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, Fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol. Oncol.112(3), 444–449 (2009).
   PubMedGoogle Scholar
• Elit L, Oliver TK, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer109(4), 692–702 (2007).
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase 3, open-label, randomised controlled trial. Lancet374(9698), 1331–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol.(Meeting Abstracts)28(18 Suppl.), LBA1 (2010).
   Web of Science ®Google Scholar
• Pölcher M, Eckhardt M, Coch C et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol.66(1), 203–207 (2010).
   PubMed Web of Science ®Google Scholar